StefanCharlesGrantMD

Oncology • New Orleans, LA

Associate Professor, Medicine, Associate Director Clinical and Translational Research and IP Development, Wake Forest Baptist Comprehensive Cancer Center

Join to view full profile

Dr. Grant is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grant's full profile

Already have an account?

Office
1430 Tulane Ave
# 8016
New Orleans, LA 70112
Phone+1 504-988-7518

Fax+1 504-988-8252

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1992
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1985 - 1988
University of the WitwatersrandClass of 1981

Certifications & Licensure

NY State Medical License 1988 - 2026
LA State Medical License 2023 - 2025
NC State Medical License 2014 - 2024
OH State Medical License 2022 - 2024
AL State Medical License 2011 - 2014
PA State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1, Phase 2
Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer Start of enrollment: 2016 Jan 01
Withdrawn
Phase 2
Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 Start of enrollment: 2015 May 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Start of enrollment: 2015 Aug 06
Completed
Phase 2
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer Start of enrollment: 2018 Jun 01
Withdrawn
Phase 1, Phase 2
Precision Medicine for Patients With Identified Actionable Mutations Start of enrollment: 2020 Apr 22
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.
Thomas J George, Tara L Lin, Tricia Adrales Bentz, Stefan Grant, Collette M Houston
JNCI Cancer Spectrum. 2023-07-03
1 citations
Team-Based Hospice Referrals: A Potential Quality Metric for Lung Cancer in the Immunotherapy Era.
Thomas W Lycan Jr, Alyssa Buckenheimer, Jimmy Ruiz, Gregory Russell, Andy Shipe Dothard
The American Journal of Hospice & Palliative Care. 2023-01-01
8 citations
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152).
Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, Shuli Li, Ilana F Gareen
Cancer. 2022-04-01

Press Mentions

Genetic Alterations in Lung Cancers Help Select TreatmentMay 20th, 2014
74 Oncologists on the MoveOctober 11th, 2023

Professional Memberships

American Society of Clinical Oncology - ASCO
Member